Welp. Scientists Just Announced the Doomsday Clock Is Closer Than Ever to Midnight.

Behind closed doors with the experts who study the end of the world—and what they know about humanity’s capacity for survival ...

Johnson & Johnson: RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
RMD Open

Which arthralgia patients benefit most in reduction of subclinical joint inflammation by methotrexate treatment: results from the TREAT EARLIER trial

Objectives The TREAT EARLIER trial showed in clinically suspect arthralgia (CSA) that methotrexate induced reductions in ...
BMJ Open

Subsequent risk of non-keratinocyte skin cancers in adult cancer survivors: a SEER-based cohort study

Objective To characterise the risk of subsequent primary non-keratinocyte skin cancers (NKSCs) among adult-onset cancer survivors. Design Data analysis of this population-based cohort study was ...
Scientific Research Publishing

Barriers to Effective Nutrition Education in Basic Schools in Ghana: A Conceptual Review ()

Nutrition Education, Basic Schools in Ghana, School Health Policy, Critical Curriculum, Health Belief Model, Social Cognitive Theory Share and Cite: Abor-Adjei, F. (2026) Barriers to Effective ...

Plot twist: it's time to cast your vote in the Herald's short story competition

We've narrowed down the field, but the story is not yet truly complete. You can step into the role of literary critic. Dive ...
MyHorryNews

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months ...